Annexon, Inc.

Annexon, Inc. (Nasdaq: ANXN) is a clinical-stage biopharmaceutical company developing targeted immunotherapies for complement-mediated neuroinflammatory diseases affecting approximately ten million people worldwide. The company's website is www.annexon.com.

Annexon's proprietary platform targets C1q, the initiating molecule of the classical complement pathway, with the goal of stopping neuroinflammation at its source while preserving beneficial immune functions. The company's approach aims to provide complete protection against complement-mediated disorders of the body, brain, and eye by blocking the early classical cascade and all downstream pathway components.

The company's pipeline includes two late-stage registrational programs. Tanruprubart is an investigational targeted immunotherapy delivered via single infusion for Guillain-Barré Syndrome, an acute neuromuscular emergency affecting approximately 150,000 people annually worldwide. In Phase 3 trials, approximately ninety percent of GBS patients treated with tanruprubart improved by week one, with more than twice as many treated patients achieving normal health status at week twenty-six compared to placebo. The company filed a Marketing Authorization Application with the European Medicines Agency in January 2026 and plans to submit a biologics license application to the FDA in 2026. Tanruprubart has received Fast Track and orphan drug designations from the FDA and orphan designation from the EMA.

Vonaprument is an investigational neuroprotective inhibitor of C1q delivered intravitreally for dry age-related macular degeneration with geographic atrophy, affecting more than eight million people worldwide. In Phase 2 trials, vonaprument demonstrated significant vision preservation and reduced the risk of fifteen-letter vision loss by more than seventy percent. The company completed enrollment of 659 patients in the Phase 3 ARCHER II trial in July 2025, with topline data expected in the fourth quarter of 2026. Vonaprument received Priority Medicine designation from the EMA and is the first and only therapeutic candidate for geographic atrophy to receive this designation.

The company is also developing ANX1502, a novel oral small molecule inhibiting activated C1s for autoimmune conditions, currently in Phase 1 and proof-of-concept studies. Annexon holds worldwide development and commercialization rights to all product candidates through exclusive licenses and maintains broad intellectual property protection for its platform and candidates.